# Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery

> **NCT06277921** · — · COMPLETED · sponsor: **P. Herzen Moscow Oncology Research Institute** · enrollment: 230 (actual)

## Conditions studied

- Esophageal Cancer
- Oesophageal Cancer
- Siewert Type I Adenocarcinoma of Esophagogastric Junction
- Siewert Type III Adenocarcinoma of Esophagogastric Junction

## Interventions

- **PROCEDURE:** Elective Surgery for gastric cancer

## Key facts

- **NCT ID:** NCT06277921
- **Lead sponsor:** P. Herzen Moscow Oncology Research Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-18
- **Primary completion:** 2024-09-18
- **Final completion:** 2025-01-20
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2025-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06277921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06277921, "Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06277921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*